Literature DB >> 22627902

A new general biomarker-based incidence estimator.

Reshma Kassanjee1, Thomas A McWalter, Till Bärnighausen, Alex Welte.   

Abstract

BACKGROUND: Estimating disease incidence from cross-sectional surveys, using biomarkers for "recent" infection, has attracted much interest. Despite widespread applications to HIV, there is currently no consensus on the correct handling of biomarker results classifying persons as "recently" infected long after the infections occurred.
METHODS: We derive a general expression for a weighted average of recent incidence that-unlike previous estimators-requires no particular assumption about recent infection biomarker dynamics or about the demographic and epidemiologic context. This is possible through the introduction of an explicit timescale T that truncates the period of averaging implied by the estimator.
RESULTS: The recent infection test dynamics can be summarized into 2 parameters, similar to those appearing in previous estimators: a mean duration of recent infection and a false-recent rate. We identify a number of dimensionless parameters that capture the bias that arises from working with tractable forms of the resulting estimator and elucidate the utility of the incidence estimator in terms of the performance of the recency test and the population state. Estimation of test characteristics and incidence is demonstrated using simulated data. The observed confidence interval coverage of the test characteristics and incidence is within 1% of intended coverage.
CONCLUSIONS: Biomarker-based incidence estimation can be consistently adapted to a general context without the strong assumptions of previous work about biomarker dynamics and epidemiologic and demographic history.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627902      PMCID: PMC3500970          DOI: 10.1097/EDE.0b013e3182576c07

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  26 in total

Review 1.  Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation.

Authors:  Michael P Busch; Christopher D Pilcher; Timothy D Mastro; John Kaldor; Gaby Vercauteren; William Rodriguez; Christine Rousseau; Thomas M Rehle; Alex Welte; Megan D Averill; Jesus M Garcia Calleja
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

2.  Using tests for recent infection to estimate incidence: problems and prospects for HIV.

Authors:  A Welte; T A McWalter; O Laeyendecker; T B Hallett
Journal:  Euro Surveill       Date:  2010-06-17

3.  Estimation of the distribution of infection times using longitudinal serological markers of HIV: implications for the estimation of HIV incidence.

Authors:  C Sommen; D Commenges; S Le Vu; L Meyer; A Alioum
Journal:  Biometrics       Date:  2010-08-23       Impact factor: 2.571

4.  Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays.

Authors:  Wolfgang Hladik; Dennis Olara; Jonathan Mermin; David Moore; Willy Were; Lorraine Alexander; Robert Downing
Journal:  AIDS Res Hum Retroviruses       Date:  2011-03-11       Impact factor: 2.205

5.  Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection.

Authors:  Kelly A Curtis; M Susan Kennedy; Man Charurat; Abdulsalami Nasidi; Kevin Delaney; Thomas J Spira; S Michele Owen
Journal:  AIDS Res Hum Retroviruses       Date:  2011-06-17       Impact factor: 2.205

Review 6.  HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis.

Authors:  Till Bärnighausen; Thomas A McWalter; Zachary Rosner; Marie-Louise Newell; Alex Welte
Journal:  Epidemiology       Date:  2010-09       Impact factor: 4.822

7.  Estimating HIV incidence based on combined prevalence testing.

Authors:  Raji Balasubramanian; Stephen W Lagakos
Journal:  Biometrics       Date:  2009-04-13       Impact factor: 2.571

8.  Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers.

Authors:  Sarah L Braunstein; Denis Nash; Andrea A Kim; Ken Ford; Lambert Mwambarangwe; Chantal M Ingabire; Joseph Vyankandondera; Janneke H H M van de Wijgert
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

9.  A comparison of biomarker based incidence estimators.

Authors:  Thomas A McWalter; Alex Welte
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

Review 10.  Estimating the HIV incidence rate: recent and future developments.

Authors:  Timothy B Hallett
Journal:  Curr Opin HIV AIDS       Date:  2011-03       Impact factor: 4.283

View more
  50 in total

1.  Strengthening HIV surveillance: measurements to track the epidemic in real time.

Authors:  Usangiphile E Buthelezi; Candace L Davidson; Ayesha Bm Kharsany
Journal:  Afr J AIDS Res       Date:  2016-07       Impact factor: 1.300

2.  Short Communication: Defining optimality of a test for recent infection for HIV incidence surveillance.

Authors:  Reshma Kassanjee; Thomas A McWalter; Alex Welte
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-26       Impact factor: 2.205

3.  Correlates of HIV infection in adolescent girls and young women in Lesotho: results from a population-based survey.

Authors:  Andrea Low; Kyaw Thin; Stefania Davia; Joanne Mantell; Masebeo Koto; Stephen McCracken; Puleng Ramphalla; Limpho Maile; Nahima Ahmed; Hetal Patel; Bharat Parekh; Neway Fida; Amee Schwitters; Koen Frederix
Journal:  Lancet HIV       Date:  2019-08-14       Impact factor: 12.767

4.  Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence.

Authors:  Katherine E Schlusser; Jacob Konikoff; Allison R Kirkpatrick; Charles Morrison; Tsungai Chipato; Pai-Lien Chen; Marshall Munjoma; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2017-03-20       Impact factor: 2.205

5.  Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.

Authors:  Andrew F Longosz; Charles S Morrison; Pai-Lien Chen; Hilmarie H Brand; Eric Arts; Immaculate Nankya; Robert A Salata; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-19       Impact factor: 2.205

6.  Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms.

Authors:  Eduard Grebe; Alex Welte; Jake Hall; Sheila M Keating; Shelley N Facente; Kara Marson; Jeffrey N Martin; Susan J Little; Matthew A Price; Esper G Kallas; Michael P Busch; Christopher D Pilcher; Gary Murphy
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

7.  Cross-Sectional HIV Incidence Estimation with Missing Biomarkers.

Authors:  Doug Morrison; Oliver Laeyendecker; Jacob Konikoff; Ron Brookmeyer
Journal:  Stat Commun Infect Dis       Date:  2018-07-31

8.  Viral load criteria and threshold optimization to improve HIV incidence assay characteristics.

Authors:  Reshma Kassanjee; Christopher D Pilcher; Michael P Busch; Gary Murphy; Shelley N Facente; Sheila M Keating; Elaine Mckinney; Kara Marson; Matthew A Price; Jeffrey N Martin; Susan J Little; Frederick M Hecht; Esper G Kallas; Alex Welte
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

9.  Improvements in the continuum of HIV care in an inner-city emergency department.

Authors:  Gabor D Kelen; Yu-Hsiang Hsieh; Richard E Rothman; Eshan U Patel; Oliver B Laeyendecker; Mark A Marzinke; William Clarke; Teresa Parsons; Jordyn L Manucci; Thomas C Quinn
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

10.  Estimating HIV Incidence Using a Cross-Sectional Survey: Comparison of Three Approaches in a Hyperendemic Setting, Ndhiwa Subcounty, Kenya, 2012.

Authors:  Stéphanie Blaizot; Andrea A Kim; Clement Zeh; Benjamin Riche; David Maman; Kevin M De Cock; Jean-François Etard; René Ecochard
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-13       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.